What are the side effects of cyclobenzaprine?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: August 18, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Cyclobenzaprine Side Effects

Cyclobenzaprine commonly causes drowsiness (29-38%), dry mouth (21-32%), and fatigue (6%), with these adverse effects being dose-dependent and more pronounced at higher doses. 1

Common Side Effects

  • Drowsiness/Sedation: Occurs in 29% of patients at 5mg dose and 38% at 10mg dose 1
  • Dry Mouth: Affects 21% of patients at 5mg dose and 32% at 10mg dose 1
  • Fatigue: Reported by 6% of patients 1
  • Headache: Occurs in approximately 5% of patients 1
  • Dizziness: Reported in 11% of patients in clinical trials, 3% in surveillance programs 1

Less Common Side Effects (1-3% incidence)

  • Abdominal pain
  • Acid regurgitation
  • Constipation
  • Diarrhea
  • Nausea
  • Irritability
  • Decreased mental acuity
  • Nervousness
  • Upper respiratory infection
  • Pharyngitis 1

Serious Adverse Effects

Cardiovascular Effects

Cyclobenzaprine is structurally related to tricyclic antidepressants and may cause:

  • Tachycardia
  • Arrhythmias
  • Prolonged conduction time
  • Hypotension
  • Palpitations 1

Neurological/Psychiatric Effects

  • Seizures
  • Ataxia
  • Tremors
  • Disorientation
  • Anxiety
  • Agitation
  • Hallucinations
  • Confusion 1

Serotonin Syndrome

Potentially life-threatening when combined with:

  • SSRIs
  • SNRIs
  • Tricyclic antidepressants
  • Tramadol
  • Bupropion
  • MAO inhibitors (contraindicated) 1

Signs of serotonin syndrome include:

  • Mental status changes
  • Autonomic instability
  • Neuromuscular abnormalities
  • Gastrointestinal symptoms 1

Dose-Related Side Effects

The incidence of side effects is dose-dependent, with higher doses causing more adverse effects. A 5mg TID regimen has been shown to be as effective as 10mg TID but with fewer sedative effects 2. In overdose cases, cyclobenzaprine does not typically produce life-threatening cardiovascular or neurologic effects at doses less than 1g 3.

Mechanism of Side Effects

Recent research has identified that cyclobenzaprine is a potent non-competitive antagonist of histamine H1 receptors, which likely explains its significant sedative effects 4. The anticholinergic side effects (dry mouth, constipation, blurred vision) are related to its structural similarity to tricyclic antidepressants 5, 6.

Special Considerations

  • Elderly patients: Should start with lower doses (5mg) due to increased risk of side effects 7
  • Liver impairment: Use with caution as metabolism is primarily hepatic 7
  • Drug interactions: Avoid concomitant use with MAO inhibitors and use caution with other serotonergic medications 1
  • Fibromyalgia patients: The European League Against Rheumatism (EULAR) gives only a weak recommendation for cyclobenzaprine use in fibromyalgia, noting that 85% of patients experience side effects and 29% discontinue treatment due to adverse events 8

Duration and Discontinuation

  • Short-term use (≤21 days) is recommended whenever possible 7
  • Abrupt discontinuation after prolonged use may cause withdrawal symptoms including malaise, nausea, and headache 7
  • Tapering is recommended over 2-3 weeks to prevent withdrawal symptoms 7

When prescribing cyclobenzaprine, the benefits must be weighed against these potential side effects, particularly in elderly patients or those with pre-existing conditions that may increase sensitivity to anticholinergic or sedative effects.

References

Research

Cyclobenzaprine: a new look at an old pharmacological agent.

Expert review of clinical pharmacology, 2009

Research

A review of three commonly prescribed skeletal muscle relaxants.

Journal of back and musculoskeletal rehabilitation, 2000

Guideline

Management of Muscle Spasticity in Multiple Sclerosis

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.